COMMUNIQUÉS West-GlobeNewswire

PharmaTher Announces Update on FDA New Drug Application for Ketamine

04/09/2024 - 14:00

TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced an update for its New Drug Application [...]

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

04/09/2024 - 14:00

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific [...]

Nanocarry Therapeutics' Brain Penetrating Nanoplatform Selected by the NCI Nanotechnology Characterization Laboratory for its Preclinical Characterization Program

04/09/2024 - 14:00

Program Will Facilitate Filing an IND Application Toward Human Clinical Trials NESS ZIONA, Israel, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Nanocarry Therapeutics, a pioneering biopharmaceutical company focused on advancing [...]

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

04/09/2024 - 14:00

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

04/09/2024 - 14:00

WASHINGTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today [...]

Ovid Therapeutics to Present at Upcoming September Investor Conferences

04/09/2024 - 14:00

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today [...]

Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

04/09/2024 - 14:00

WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced [...]

Solid Biosciences to Participate at Upcoming Investor Conferences

04/09/2024 - 14:00

CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]

OncoC4 Announces First Patient Dosed in Phase 1 Trial for Novel SIGLEC10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors

04/09/2024 - 14:00

ONC-841 is a potential first-in-class SIGLEC10 antibody with broad application in oncology Designed to break tumor evasion of the immune system, ONC-841 can rejuvenate anti-tumor T cells, NK cells and macrophages within [...]

Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

04/09/2024 - 14:00

CUPERTINO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]

CytomX Therapeutics to Present at Upcoming September Investor Conferences

04/09/2024 - 14:00

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will [...]

Collegium Completes Acquisition of Ironshore Therapeutics

04/09/2024 - 14:00

– Adds Commercial Product Jornay PM ® , Establishing Collegium’s Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition – – 2024 [...]

ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

04/09/2024 - 14:00

Patients can request a prescription from their existing healthcare provider, or meet with a physician virtually, to request a prescription for neffy ahead of product availability expected by late September Visit neffy . [...]

Bionano to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference

04/09/2024 - 14:00

SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 26 th [...]

ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi

04/09/2024 - 14:00

Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal antibody in patients with multiple myeloma SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE [...]

Biongevity Enhances Longevity Strategy with Harish Consul as Chief Venture Capital Advisor

04/09/2024 - 15:49

A Strategic Move to Accelerate Global Growth for the BioAro Group of Companies CALGARY, Alberta, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biongevity, a leader in precision health and longevity medicine, is pleased to announce [...]

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

04/09/2024 - 15:25

KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the [...]

Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference

04/09/2024 - 15:20

SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on [...]

Olon Continues its Growth Path and Announces a New Acquisition

04/09/2024 - 11:00

Olon, the leading chemical-pharmaceutical group in the production and development of active pharmaceutical ingredients (APIs) and part of the holding company P&R, continues its growth path and announces a new [...]